Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: The FANTOM II study

Aims: FANTOM II is a prospective multicentre trial assessing the safety and efficacy of the Fantom siroli-mus-eluting bioresorbable coronary scaffold (BRS). The present substudy focuses on the six- and nine-month IVUS findings. Methods and results: A total of 240 patients with de novo coronary artery lesions presenting with stable or unstable disease were included in two sequential cohorts (cohort A [n=117] and cohort B [n=123]) in which angiographic follow-up was performed at either six or nine months, respectively. Matched IVUS data were available for 35 paired cases in cohort A and 26 paired cases in cohort B. At six months, mean and minimum scaffold area (SA) decreased from 6.09±1.08 mm ² to 5.88±1.07 mm ² , p=0.009, and 5.27±0.99 mm ² to 5.05±0.99 mm ² , p=0.01, respectively. At nine months, no significant change in mean scaffold and minimum scaffold area was observed (6.46±1.11 mm ² to 6.38±0.96 mm ² ; p=0.35, and 5.45±1.00 mm ² to 5.36±0.86 mm ² ; p=0.32, respectively). Neointimal hyperplasia area was low at both six (0.11±0.12 mm ² ) and nine months (0.20±0.21 mm ² ), as was in-scaffold obstruction volume (1.94±2.25% at six months, and 3.40±4.11% at nine months). Conclusions: The use of the Fantom BRS in stable coronary artery disease was associated with low rates of neointimal hyperplasia volume and in-scaffold volume obstruction at both six and nine months.